A new diagnostic opportunity in uro-oncology
Bladder cancer requires precise, repeatable diagnostic and monitoring tools that can be integrated into real clinical workflows. Diagnostic laboratories can play a key role in the adoption of non-invasive molecular solutions that bring value to hospitals, specialists and patients.
High follow-up need
Bladder cancer requires frequent and prolonged monitoring, creating recurring demand for more accessible and repeatable diagnostic solutions.
Non-invasive sample
The use of urine facilitates sample collection, reduces patient friction and supports longitudinal monitoring models.
Value for diagnostic networks
The incorporation of specialized molecular tests can differentiate service portfolios and open new clinical collaboration opportunities.
From sample to report
BlaDimiR is based on a molecular workflow compatible with laboratories working with biological samples, amplification technologies and biomarker-based analysis.
Urine sample
Simple, non-invasive collection suitable for diagnostic and monitoring workflows.
Molecular processing
Sample preparation oriented toward the analysis of urinary miRNA biomarkers.
RT-qPCR
Widely used technology in molecular diagnostic laboratories.
Results report
Clear, actionable results designed to support clinical decision-making and patient monitoring.
1
2
3
4
Operational and strategic value for laboratories
New specialized diagnostic line
Incorporation of a differentiated molecular solution in uro-oncology.
Compatible molecular workflow
Designed to adapt to laboratories with experience in molecular techniques.
Recurring revenue potential
Application in diagnosis, follow-up and longitudinal patient monitoring.
Competitive differentiation
Positioning against conventional solutions and invasive procedures.
Scalability
Potential deployment across laboratory networks, hospitals and diagnostic partners.
Potential deployment across laboratory networks, hospitals and diagnostic partners.
Explore collaboration and validation opportunities
Danae Urogenomics works with laboratories, reference centers and diagnostic partners to bring urinary miRNA innovation into clinical practice.
Request information for laboratories
Molecular diagnostics for bladder cancer based on urine miRNA biomarkers.
BlaDimiR by Danae Urogenomics
Platform
Opportunities
Contact
© 2026 Danae Urogenomics. All rights reserved.